# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility...
Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians differentiate b...